Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.01B | 738.54M | 625.40M | 1.04B | 1.36M |
Gross Profit | 871.01M | 610.10M | 482.01M | 977.37M | 1.36M |
EBITDA | -463.49M | -516.55M | -808.28M | 16.23M | -453.44M |
Net Income | -440.63M | -631.26M | -871.65M | -66.68M | -463.17M |
Balance Sheet | |||||
Total Assets | 9.41B | 9.92B | 10.32B | 7.40B | 4.54B |
Cash, Cash Equivalents and Short-Term Investments | 7.29B | 8.22B | 9.01B | 6.25B | 3.97B |
Total Debt | 1.27B | 1.35B | 1.25B | 1.27B | 1.17B |
Total Liabilities | 2.66B | 2.74B | 2.68B | 1.74B | 1.38B |
Stockholders Equity | 6.73B | 7.15B | 7.60B | 5.60B | 3.10B |
Cash Flow | |||||
Free Cash Flow | -443.78M | -926.00M | -935.88M | -11.00K | -423.79M |
Operating Cash Flow | -365.55M | -671.34M | -565.55M | 167.06M | -172.52M |
Investing Cash Flow | 1.11B | 666.91M | -1.73B | -1.73B | -1.11B |
Financing Cash Flow | -285.60M | 1.31M | 3.09B | 2.54B | 2.24B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | 42.20B | 47.42 | 27.23% | ― | 2.57% | 18.79% | |
55 Neutral | 20.69B | -72.04 | -20.82% | ― | 964.40% | 65.90% | |
53 Neutral | 11.68B | -20.40 | 0.00% | ― | 1219.19% | 25.15% | |
46 Neutral | 20.24B | -26.11 | -25.57% | ― | 102.73% | 38.42% | |
45 Neutral | HK$26.25B | ― | -3.06% | ― | 68.88% | 55.64% | |
45 Neutral | 27.84B | -19.21 | -153.46% | ― | -56.94% | -190.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
InnoCare Pharma Ltd. has announced the grant of 2,467,550 Restricted Shares to 91 Incentive Participants as part of its 2024 RMB Share Incentive Scheme. This grant, representing approximately 0.14% of the company’s total issued shares, aims to incentivize key personnel and aligns with company and individual performance targets. The initiative is expected to bolster employee motivation and align interests with shareholders, potentially enhancing the company’s operational performance and market positioning.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$25.20 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Ltd. announced the grant of 210,000 Restricted Share Units (RSUs) under its 2023 Share Award Scheme to three employees, including a connected person of the company. This grant, representing approximately 0.01% of the company’s total shares, aims to incentivize key personnel through a combination of time-based and performance-based vesting conditions. The performance targets are aligned with the company’s corporate goals, such as operating revenue and clinical trial advancements, as well as individual performance metrics, reflecting InnoCare’s commitment to driving commercialization and research progress.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$25.20 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Ltd. reported a significant increase in revenue for the first half of 2025, with a 74.3% rise to RMB731.4 million compared to the same period in 2024. This growth was primarily driven by the strong sales performance of Orelabrutinib and licensing revenue from Prolium. Despite the increase in revenue, the company reported a loss of RMB35.6 million, although this was a substantial improvement from the previous year’s loss of RMB267.9 million. The financial results highlight the company’s expanding market presence and the growing acceptance of its products, particularly Orelabrutinib, which saw a 52.8% increase in sales due to expanded coverage and a higher number of patients treated.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$25.20 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Ltd. has announced that its board of directors will meet on August 19, 2025, to consider and approve the interim financial results for the first half of the year. This meeting could have significant implications for the company’s financial transparency and investor relations, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Ltd. announced that all proposed resolutions at its Annual General Meeting held on June 20, 2025, were passed by shareholders. The resolutions included approval of financial statements, annual and work reports, a profit distribution plan, and mandates for share allotment and repurchase. Additionally, several directors were re-elected, and the board was authorized to fix directors’ remuneration. This successful AGM reflects strong shareholder support and positions the company for continued operational and strategic initiatives.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.